United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - milprosa™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women up to and including 34 years of age. limitation of use efficacy in women 35 years of age and older has not been established. milprosa is contraindicated in women with: - known sensitivity to progesterone or any of the ingredients of milprosa [see description (11)] - undiagnosed vaginal bleeding - severe hepatic impairment or disease - known or suspected malignancy of the breast - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events risk summary milprosa is indicated to support embryo implantation and early pregnancy as part of an assisted reproductive technology treatment program in vitro fertilization (ivf) with or without intracytoplasmic sperm injection (icsi) and embryo transfer for infertile women. maternal risks a

Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - obstetrics & gynaecology - reusable injection pen intended for the administration of subcutaneous injections of rekovelle provided by ferring pharmaceuticals a/s.

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - nocdurna is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. in the nocdurna clinical trials nocturnal polyuria was defined as night-time urine production exceeding one-third of the 24-hour urine production. before starting nocdurna: - evaluate the patient for possible causes for the nocturia, including excessive fluid intake prior to bedtime, and address other treatable causes of nocturia. - confirm the diagnosis of nocturnal polyuria with a 24-hour urine collection, if one has not been obtained previously. nocdurna is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: - hyponatremia or a history of hyponatremia [see warnings and precautions (5.1)] . - polydipsia - concomitant use with loop diuretics [see warnings and precautions (5.1)] - concomitant use with systemic or inhaled glucocorticoids [see warnings and precautions (5.2), drug interactions (7.1)] - renal impairment with estimate

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - ornipressin, quantity: 5 iu/ml - injection, solution - excipient ingredients: sodium acetate; glacial acetic acid; sodium chloride; water for injections - local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem plastic surgery: hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc obstetrics/gynaecology: vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy. ent surgery: tonsillectomy, submucous resection of septum, myringoplasty etc. other types of surgery: neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar).

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - ganirelix acetate (unii: 56u7906fqw) (ganirelix - unii:ix503l9wn0) - ganirelix acetate injection is indicated for the inhibition of premature lh surges in women undergoing controlled ovarian hyperstimulation. ganirelix acetate injection is contraindicated under the following conditions: - known hypersensitivity to ganirelix acetate or to any of its components. - known hypersensitivity to gnrh or any other gnrh analog. - known or suspected pregnancy (see precautions).

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - endometrin® (progesterone) is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women. endometrin is contraindicated in individuals with any of the following conditions: - previous allergic reactions to progesterone or any of the ingredients of endometrin [see description (11) ] - undiagnosed vaginal bleeding - known missed abortion or ectopic pregnancy - liver disease - known or suspected malignancy of the breast or genital organs - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events endometrin has been used to support embryo implantation and maintain clinical pregnancy in one clinical study. the live birth outcomes of these pregnancies were as follows: - among the 404 subjects treated with endometrin twice daily, 143 subjects had live births consisting of 85 singletons, 56 twins, and 2 triplets. in this treatment group, 1

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - quinagolide as hydrochloride - tablets - quinagolide as hydrochloride 0.025 mg - quinagolide - quinagolide - second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).